The disclosure relates to surgical stapling devices, and more particularly, to assemblies and methods for detachably securing or retaining a staple line buttress assembly to a surgical stapling device.
Surgical stapling devices are employed by surgeons to sequentially or simultaneously apply one or more rows of fasteners, e.g., staples or two-part fasteners, to body tissue for the purpose of joining segments of body tissue together. When stapling relatively thin or fragile tissues, it is important to effectively seal the staple line against air or fluid leakage. Additionally, it is often necessary to reinforce the staple line against the tissue to inhibit tears in the tissue or pulling of the staples through the tissue. One method of inhibiting tears or pull through involves the placement of a biocompatible reinforcing material or “buttress” material between the staples and the underlying tissue. In this method, a layer of buttress assembly is placed against the tissue and the tissue is stapled in a conventional manner.
Accordingly, new systems and methods that enable easy and efficient attachment and removal of a buttress assembly to a surgical stapling device would be desirable.
In accordance with the disclosure, a surgical kit includes a surgical stapling device and a loading assembly. The surgical stapling device includes a tool assembly and a buttress material. The tool assembly includes first and second jaw members that are transitionable between open and closed configurations. The first jaw member supports a staple cartridge that includes a retention assembly. The retention assembly includes a cam block including a pair of protrusions and a spring biasing the cam block towards the second jaw member. The buttress material includes proximal and distal portions. The proximal portion defines bores laterally spaced apart and configured to receive the pair of protrusions of the cam block. The distal portion defines a cavity to be placed over a distal end portion of the staple cartridge. The loading assembly includes a housing defining a chamber configured to receive a portion of the buttress material. The housing includes a proximal portion defining a slot configured to receive the buttress material therethrough and the pair of protrusions of the cam block.
In an aspect, the distal portion of the buttress material may have a weakened portion extending axially from the cavity.
In another aspect, the housing of the loading assembly may include a pair of lateral tabs on lateral sides of the housing. The staple cartridge may be positioned within the pair of lateral tabs.
In yet another aspect, the proximal portion of the housing may have a tapered surface.
In still yet another aspect, the tapered surface of the proximal portion of the housing may define an opening.
In still yet another aspect, the spring of the retention assembly may be a leaf spring.
In still yet another aspect, at least one protrusion of the pair of protrusions of the retention assembly may have a tapered portion.
In an aspect, at least one protrusion of the pair of protrusions may define a notch positioned to receive a portion of the buttress material.
In another aspect, the staple cartridge may include an inner wall defining a camming slot, and the cam block may include a camming portion configured to slidably engage the camming slot of the inner wall.
In yet another aspect, the buttress material may be formed of an elastic material and the buttress material may be in tension when secured to the staple cartridge.
In stilly yet another aspect, the pair of protrusions of the cam block may be secured to the buttress material via interference or friction fit.
In accordance with another aspect of the disclosure, a buttress assembly for use with a surgical stapling device includes a buttress material and a loading assembly. The buttress material includes proximal and distal portions. The proximal portion defines bores laterally spaced apart. The distal portion defines a cavity. The loading assembly includes a housing defining a chamber to receive a portion of the buttress material. The housing includes proximal and distal sections. The proximal section defines a slot configured to be in registration with the bores of the buttress material when the portion of the buttress material is received in the chamber of the loading assembly. The slot is dimensioned to receive the buttress material therethrough.
In an aspect, the housing may have tabs on lateral sides thereof.
In another aspect, the proximal section of the housing may have a tapered surface.
In yet another aspect, the tapered surface of the housing may have an opening.
In still yet another aspect, the buttress material may be bioabsorbable.
In still yet another aspect, the buttress material may have perforations along a central axis of the buttress material.
In still yet another aspect, the cam block may have a generally U-shaped profile.
In accordance with yet another aspect of the disclosure, a tool assembly of a surgical device includes first and second jaw members and a clamping member. The second jaw member is movable between open and closed configurations in relation to the first jaw member. The second jaw member includes a spring to bias the second jaw member towards the open configuration. The clamping member is operatively coupled to the first and second jaw members such that axial displacement of the clamping member transitions the second jaw member between the open and closed configurations.
In an aspect, the spring may be disposed laterally of the clamping member.
The above and other aspects and features of this disclosure will become more apparent in view of the following detailed description when taken in conjunction with the accompanying drawings wherein like reference numerals identify similar or identical elements.
The surgical stapling device including a buttress retention assembly disclosed herein is described in detail with reference to the drawings, in which like reference numerals designate identical or corresponding elements in each of the several views. As used herein, the term “distal” refers to the portion of the device that is being described which is farther from a user in a conventional use of the surgical stapling device, while the term “proximal” refers to the portion of the device that is being described which is closer to a user in a conventional use of the surgical stapling device. In addition, the terms parallel and perpendicular are understood to include relative configurations that are substantially parallel and substantially perpendicular up to about + or −10 degrees from true parallel and true perpendicular. Further, to the extent consistent, any or all of the aspects detailed herein may be used in conjunction with any or all of the other aspects detailed herein.
With reference to
With continued reference to
The buttress material 310 is detachably securable to the tool assembly 107. To this end, the staple cartridge 112 includes the retention assembly 550 (
In use, the proximal portion 310a of the buttress material 310 is placed in the chamber 607 (
It is further contemplated that the buttress material 310 may be made from any biocompatible natural or synthetic material. The material from which the buttress material 310 is formed may be bioabsorbable or non-bioabsorbable. It should be understood that any combination of natural, synthetic, bioabsorbable and non-bioabsorbable materials may be used to form the buttress material 310.
Some non-limiting examples of materials from which the buttress material 310 may be made include but are not limited to poly(lactic acid), poly (glycolic acid), poly (hydroxybutyrate), poly (phosphazine), polyesters, polyethylene glycols, polyethylene oxides, polyacrylamides, polyhydroxyethylmethylacrylate, polyvinylpyrrolidone, polyvinyl alcohols, polyacrylic acid, polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly (ether-esters), polyalkylene oxalates, polyamides, poly (iminocarbonates), polyalkylene oxalates, polyoxaesters, polyorthoesters, polyphosphazenes and copolymers, block copolymers, homopolymers, blends and combinations thereof.
In aspects, natural biological polymers are used in forming the buttress material 310. Suitable natural biological polymers include, but are not limited to, collagen, gelatin, fibrin, fibrinogen, elastin, keratin, albumin, hydroxyethyl cellulose, cellulose, hydroxypropyl cellulose, carboxyethyl cellulose, chitan, chitosan, and combinations thereof. In addition, the natural biological polymers may be combined with any of the other polymeric materials described herein to produce the buttress material 310.
The buttress material 310 may be porous or non-porous, or combinations of porous and non-porous layers. Where the buttress material 310 is non-porous, the buttress material 310 may retard or inhibit tissue ingrowth from surrounding tissues thereby acting as an adhesion barrier and inhibiting the formation of unwanted scar tissue. Thus, in aspects, the buttress material 310 possesses anti-adhesion properties. Techniques for forming non-porous layers from such materials are within the purview of those skilled in the art and include, for example, casting, molding, and the like.
In aspects, the buttress material 310 is porous and possesses hemostatic properties. Where the buttress material 310 is porous, it has openings or pores over at least a portion of a surface thereof. Suitable materials for forming the porous layer include, but are not limited to foams (e.g., open or closed cell foams). In aspects, the pores may be in sufficient number and size so as to interconnect across the entire thickness of the porous layer. In other aspects, the pores do not interconnect across the entire thickness of the porous layer. In yet other aspects, the pores do not extend across the entire thickness of the porous layer, but rather are present at a portion of the surface thereof. In aspects, the openings or pores are located on a portion of the surface of the porous layer, with other portions of the porous layer having a non-porous texture. Those skilled in the art reading the disclosure will envision other pore distribution patterns and configurations for the porous layer.
Where the buttress material 310 is porous, the pores may be formed using any method suitable to forming a foam or sponge including, but not limited to the lyophilization or freeze-drying of a composition. Suitable techniques for making foams are within the purview of those skilled in the art. Porous buttress material 310 can be at least 0.2 cm thick, in aspects from about 0.3 to about 1.5 cm thick. Porous buttress material 310 can have a density of not more than about 75 mg/cm2 and, in aspects below about 20 mg/cm2. The size of the pores in the porous buttress material 310 can be from about 20 μm to about 300 μm, and in certain aspects from about 100 μm to about 200 μm.
The buttress material 310 may also include a reinforcement member. The reinforcement member may be associated with a porous or non-porous layer or may be positioned between a non-porous layer and a porous layer of the buttress material 310. Alternatively, the reinforcement member may be positioned entirely within one or more of the individual layers (e.g., embedded within the porous layer, the non-porous layer, or both) of the buttress material 310. It is also envisioned that the reinforcement member may be positioned at the surface of one of the layers making up the buttress material 310 and, in aspects, may be positioned at an exterior surface of the buttress material 310.
Some suitable non-limiting examples of reinforcement members include fabrics, meshes, monofilaments, multifilament braids, chopped fibers (sometimes referred to in the art as staple fibers) and combinations thereof. Where the reinforcement member is a mesh, it may be prepared using any technique known to those skilled in the art, such as knitting, weaving, tatting, knipling, or the like. Where monofilaments or multifilament braids are used as the reinforcement member, the monofilaments or multifilament braids may be oriented in any desired manner. For example, the monofilaments or multifilament braids may be randomly positioned with respect to each other within the buttress material 310. As another example, the monofilaments or multifilament braids may be oriented in a common direction within the buttress material 310. Where chopped fibers are used as the reinforcement member, the chopped fibers may be oriented in any desired manner. For example, the chopped fibers may be randomly oriented or may be oriented in a common direction. The chopped fibers can thus form a non-woven material, such as a mat or a felt. The chopped fibers may be joined together (e.g., by heat fusing) or they may be unattached to each other. The chopped fibers may be of any suitable length. For example, the chopped fibers may be from 0.1 mm to 100 mm in length, and in some aspects, 0.4 mm to 50 mm in length. In an aspect, the buttress material 310 has randomly oriented chopped fibers that have not been previously fused together and are embedded within in the buttress material 310.
It is envisioned that the reinforcement member may be formed from any bioabsorbable, non-bioabsorbable, natural, or synthetic material previously described herein and combinations thereof. Where monofilaments or multifilament braids are used as the reinforcement member, any commercially available suture material may advantageously be employed as the reinforcement member.
In aspects, at least one bioactive agent may be combined with the buttress material 310 and/or any of the individual components (the porous layer, the non-porous layer and/or the reinforcement member) used to construct the buttress material 310. In aspects, the buttress material 310 can also serve as a vehicle for delivery of the bioactive agent. The term “bioactive agent”, as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, or fragrance. Alternatively, a bioactive agent could be any agent which provides a therapeutic or prophylactic effect such as a compound that affects or participates in tissue growth, cell growth, or cell differentiation.
Examples of classes of bioactive agents which may be utilized in accordance with the disclosure include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.
Anti-adhesive or anti-adhesion agents can be used to inhibit adhesions from forming between the buttress material 310 and the surrounding tissues opposite the target tissue. Some examples of these agents include, but are not limited to poly (vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols and combinations thereof.
Suitable antimicrobial agents which may be included as a bioactive agent in the buttress material 310 of the disclosure include triclosan, also known as 2,4,4′-trichloro-2′-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil, nonoxynol 9, fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent in the bioactive coating of the disclosure.
Other bioactive agents which may be included as a bioactive agent in the buttress material 310 in accordance with the disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.
Other examples of suitable bioactive agents which may be included in the coating composition include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (β-IFN, (α-IFN and γ-IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligonucleotides; polynucleotides; and ribozymes.
While the disclosure has been shown in the drawings, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
Number | Name | Date | Kind |
---|---|---|---|
2957353 | Babacz | Oct 1960 | A |
3111328 | Di Rito et al. | Nov 1963 | A |
3695058 | Keith, Jr. | Oct 1972 | A |
3734515 | Dudek | May 1973 | A |
3759336 | Marcovitz et al. | Sep 1973 | A |
4162399 | Hudson | Jul 1979 | A |
4606343 | Conta et al. | Aug 1986 | A |
4705038 | Sjostrom et al. | Nov 1987 | A |
4722685 | de Estrada et al. | Feb 1988 | A |
4823807 | Russell et al. | Apr 1989 | A |
4874181 | Hsu | Oct 1989 | A |
5129118 | Walmesley | Jul 1992 | A |
5129570 | Schulze et al. | Jul 1992 | A |
5152744 | Krause et al. | Oct 1992 | A |
5301061 | Nakada et al. | Apr 1994 | A |
5312023 | Green et al. | May 1994 | A |
5326013 | Green et al. | Jul 1994 | A |
5350355 | Sklar | Sep 1994 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5383880 | Hooven | Jan 1995 | A |
5389098 | Tsuruta et al. | Feb 1995 | A |
5395033 | Byrne et al. | Mar 1995 | A |
5400267 | Denen et al. | Mar 1995 | A |
5411508 | Bessler et al. | May 1995 | A |
5413267 | Solyntjes et al. | May 1995 | A |
5427087 | Ito et al. | Jun 1995 | A |
5433721 | Hooven et al. | Jul 1995 | A |
5467911 | Tsuruta et al. | Nov 1995 | A |
5476379 | Disel | Dec 1995 | A |
5487499 | Sorrentino et al. | Jan 1996 | A |
5518163 | Hooven | May 1996 | A |
5518164 | Hooven | May 1996 | A |
5526822 | Burbank et al. | Jun 1996 | A |
5529235 | Boiarski et al. | Jun 1996 | A |
5535934 | Boiarski et al. | Jul 1996 | A |
5535937 | Boiarski et al. | Jul 1996 | A |
5540375 | Bolanos et al. | Jul 1996 | A |
5540706 | Aust et al. | Jul 1996 | A |
5542594 | McKean et al. | Aug 1996 | A |
5549637 | Crainich | Aug 1996 | A |
5553675 | Pitzen et al. | Sep 1996 | A |
5562239 | Boiarski et al. | Oct 1996 | A |
5564615 | Bishop et al. | Oct 1996 | A |
5609560 | Ichikawa et al. | Mar 1997 | A |
5626587 | Bishop et al. | May 1997 | A |
5632432 | Schulze et al. | May 1997 | A |
5645209 | Green et al. | Jul 1997 | A |
5647526 | Green et al. | Jul 1997 | A |
5653374 | Young et al. | Aug 1997 | A |
5658300 | Bito et al. | Aug 1997 | A |
5662662 | Bishop et al. | Sep 1997 | A |
5667517 | Hooven | Sep 1997 | A |
5693042 | Boiarski et al. | Dec 1997 | A |
5704534 | Huitema et al. | Jan 1998 | A |
5713505 | Huitema | Feb 1998 | A |
5762603 | Thompson | Jun 1998 | A |
5779130 | Alesi et al. | Jul 1998 | A |
5782396 | Mastri et al. | Jul 1998 | A |
5782397 | Koukline | Jul 1998 | A |
5792573 | Pitzen et al. | Aug 1998 | A |
5797536 | Smith et al. | Aug 1998 | A |
5820009 | Melling et al. | Oct 1998 | A |
5863159 | Lasko | Jan 1999 | A |
5865361 | Milliman et al. | Feb 1999 | A |
5908427 | McKean et al. | Jun 1999 | A |
5954259 | Viola et al. | Sep 1999 | A |
5964774 | McKean et al. | Oct 1999 | A |
5993454 | Longo | Nov 1999 | A |
6010054 | Johnson et al. | Jan 2000 | A |
6017354 | Culp et al. | Jan 2000 | A |
6032849 | Mastri et al. | Mar 2000 | A |
6045560 | McKean et al. | Apr 2000 | A |
6090123 | Culp et al. | Jul 2000 | A |
6126651 | Mayer | Oct 2000 | A |
6129547 | Cise et al. | Oct 2000 | A |
6165169 | Panescu et al. | Dec 2000 | A |
6239732 | Cusey | May 2001 | B1 |
6241139 | Milliman et al. | Jun 2001 | B1 |
6264086 | McGuckin, Jr. | Jul 2001 | B1 |
6264087 | Whitman | Jul 2001 | B1 |
6302311 | Adams et al. | Oct 2001 | B1 |
6315184 | Whitman | Nov 2001 | B1 |
6321855 | Barnes | Nov 2001 | B1 |
6329778 | Culp et al. | Dec 2001 | B1 |
6343731 | Adams et al. | Feb 2002 | B1 |
6348061 | Whitman | Feb 2002 | B1 |
6368324 | Dinger et al. | Apr 2002 | B1 |
6371909 | Hoeg et al. | Apr 2002 | B1 |
6434507 | Clayton et al. | Aug 2002 | B1 |
6443973 | Whitman | Sep 2002 | B1 |
6461372 | Jensen et al. | Oct 2002 | B1 |
6488197 | Whitman | Dec 2002 | B1 |
6491201 | Whitman | Dec 2002 | B1 |
6533157 | Whitman | Mar 2003 | B1 |
6537280 | Dinger et al. | Mar 2003 | B2 |
6610066 | Dinger et al. | Aug 2003 | B2 |
6611793 | Burnside et al. | Aug 2003 | B1 |
6645218 | Cassidy et al. | Nov 2003 | B1 |
6654999 | Stoddard et al. | Dec 2003 | B2 |
6698643 | Whitman | Mar 2004 | B2 |
6699177 | Wang et al. | Mar 2004 | B1 |
6716233 | Whitman | Apr 2004 | B1 |
6743240 | Smith et al. | Jun 2004 | B2 |
6783533 | Green et al. | Aug 2004 | B2 |
6792390 | Burnside et al. | Sep 2004 | B1 |
6793652 | Whitman et al. | Sep 2004 | B1 |
6817508 | Racenet et al. | Nov 2004 | B1 |
6830174 | Hillstead et al. | Dec 2004 | B2 |
6846308 | Whitman et al. | Jan 2005 | B2 |
6846309 | Whitman et al. | Jan 2005 | B2 |
6849071 | Whitman et al. | Feb 2005 | B2 |
6860892 | Tanaka et al. | Mar 2005 | B1 |
6899538 | Matoba | May 2005 | B2 |
6905057 | Swayze et al. | Jun 2005 | B2 |
6959852 | Shelton, IV et al. | Nov 2005 | B2 |
6964363 | Wales et al. | Nov 2005 | B2 |
6981628 | Wales | Jan 2006 | B2 |
6981941 | Whitman et al. | Jan 2006 | B2 |
6986451 | Mastri et al. | Jan 2006 | B1 |
6988649 | Shelton, IV et al. | Jan 2006 | B2 |
7032798 | Whitman et al. | Apr 2006 | B2 |
RE39152 | Aust et al. | Jun 2006 | E |
7055731 | Shelton, IV et al. | Jun 2006 | B2 |
7059508 | Shelton, IV et al. | Jun 2006 | B2 |
7077856 | Whitman | Jul 2006 | B2 |
7111769 | Wales et al. | Sep 2006 | B2 |
7122029 | Koop et al. | Oct 2006 | B2 |
7140528 | Shelton, IV | Nov 2006 | B2 |
7141049 | Stern et al. | Nov 2006 | B2 |
7143923 | Shelton, IV et al. | Dec 2006 | B2 |
7143925 | Shelton, IV et al. | Dec 2006 | B2 |
7143926 | Shelton, IV et al. | Dec 2006 | B2 |
7147138 | Shelton, IV | Dec 2006 | B2 |
7172104 | Scirica et al. | Feb 2007 | B2 |
7225964 | Mastri et al. | Jun 2007 | B2 |
7238021 | Johnson | Jul 2007 | B1 |
7246734 | Shelton, IV | Jul 2007 | B2 |
7252660 | Kunz | Aug 2007 | B2 |
7328828 | Ortiz et al. | Feb 2008 | B2 |
7364061 | Swayze et al. | Apr 2008 | B2 |
7380695 | Doll et al. | Jun 2008 | B2 |
7380696 | Shelton, IV et al. | Jun 2008 | B2 |
7404508 | Smith et al. | Jul 2008 | B2 |
7407078 | Shelton, IV et al. | Aug 2008 | B2 |
7416101 | Shelton, IV et al. | Aug 2008 | B2 |
7419080 | Smith et al. | Sep 2008 | B2 |
7422139 | Shelton, IV et al. | Sep 2008 | B2 |
7431189 | Shelton, IV et al. | Oct 2008 | B2 |
7441684 | Shelton, IV et al. | Oct 2008 | B2 |
7448525 | Shelton, IV et al. | Nov 2008 | B2 |
7464846 | Shelton, IV et al. | Dec 2008 | B2 |
7464847 | Viola et al. | Dec 2008 | B2 |
7464849 | Shelton, IV et al. | Dec 2008 | B2 |
7481347 | Roy | Jan 2009 | B2 |
7481824 | Boudreaux et al. | Jan 2009 | B2 |
7487899 | Shelton, IV et al. | Feb 2009 | B2 |
7549564 | Boudreaux | Jun 2009 | B2 |
7565993 | Milliman et al. | Jul 2009 | B2 |
7568603 | Shelton, IV et al. | Aug 2009 | B2 |
7575144 | Ortiz et al. | Aug 2009 | B2 |
7588175 | Timm et al. | Sep 2009 | B2 |
7588176 | Timm et al. | Sep 2009 | B2 |
7637409 | Marczyk | Dec 2009 | B2 |
7641093 | Doll et al. | Jan 2010 | B2 |
7644848 | Swayze et al. | Jan 2010 | B2 |
7670334 | Hueil et al. | Mar 2010 | B2 |
7673780 | Shelton, IV et al. | Mar 2010 | B2 |
7699835 | Lee et al. | Apr 2010 | B2 |
7721931 | Shelton, IV et al. | May 2010 | B2 |
7726537 | Olson | Jun 2010 | B2 |
7738971 | Swayze et al. | Jun 2010 | B2 |
7740159 | Shelton, IV et al. | Jun 2010 | B2 |
7743960 | Whitman et al. | Jun 2010 | B2 |
7758613 | Whitman | Jul 2010 | B2 |
7766210 | Shelton, IV et al. | Aug 2010 | B2 |
7770773 | Whitman et al. | Aug 2010 | B2 |
7770775 | Shelton, IV et al. | Aug 2010 | B2 |
7793812 | Moore et al. | Sep 2010 | B2 |
7799039 | Shelton, IV et al. | Sep 2010 | B2 |
7802712 | Milliman et al. | Sep 2010 | B2 |
7803151 | Whitman | Sep 2010 | B2 |
7822458 | Webster, III et al. | Oct 2010 | B2 |
7845534 | Viola et al. | Dec 2010 | B2 |
7845537 | Shelton, IV et al. | Dec 2010 | B2 |
7857185 | Swayze et al. | Dec 2010 | B2 |
7870989 | Viola et al. | Jan 2011 | B2 |
7900805 | Shelton, IV et al. | Mar 2011 | B2 |
7905897 | Whitman et al. | Mar 2011 | B2 |
7918230 | Whitman et al. | Apr 2011 | B2 |
7922061 | Shelton, IV et al. | Apr 2011 | B2 |
7922719 | Ralph et al. | Apr 2011 | B2 |
7947034 | Whitman | May 2011 | B2 |
7950561 | Aranyi | May 2011 | B2 |
7951071 | Whitman et al. | May 2011 | B2 |
7954682 | Giordano et al. | Jun 2011 | B2 |
7959051 | Smith et al. | Jun 2011 | B2 |
7963433 | Whitman et al. | Jun 2011 | B2 |
7967178 | Scirica et al. | Jun 2011 | B2 |
7967179 | Olson et al. | Jun 2011 | B2 |
7992758 | Whitman et al. | Aug 2011 | B2 |
8011550 | Aranyi et al. | Sep 2011 | B2 |
8016178 | Olson et al. | Sep 2011 | B2 |
8016855 | Whitman et al. | Sep 2011 | B2 |
8020743 | Shelton, IV | Sep 2011 | B2 |
8025199 | Whitman et al. | Sep 2011 | B2 |
8035487 | Malackowski | Oct 2011 | B2 |
8052024 | Viola et al. | Nov 2011 | B2 |
8056787 | Boudreaux et al. | Nov 2011 | B2 |
8114118 | Knodel et al. | Feb 2012 | B2 |
8127975 | Olson et al. | Mar 2012 | B2 |
8132705 | Viola et al. | Mar 2012 | B2 |
8152516 | Harvey et al. | Apr 2012 | B2 |
8157150 | Viola et al. | Apr 2012 | B2 |
8157151 | Ingmanson et al. | Apr 2012 | B2 |
8182494 | Yencho et al. | May 2012 | B1 |
8186555 | Shelton, IV et al. | May 2012 | B2 |
8186587 | Zmood et al. | May 2012 | B2 |
8220367 | Hsu | Jul 2012 | B2 |
8235273 | Olson et al. | Aug 2012 | B2 |
8241322 | Whitman et al. | Aug 2012 | B2 |
8272554 | Whitman et al. | Sep 2012 | B2 |
8292150 | Bryant | Oct 2012 | B2 |
8292888 | Whitman | Oct 2012 | B2 |
8303581 | Arts et al. | Nov 2012 | B2 |
8342379 | Whitman et al. | Jan 2013 | B2 |
8348130 | Shah et al. | Jan 2013 | B2 |
8348855 | Hillely et al. | Jan 2013 | B2 |
8353440 | Whitman et al. | Jan 2013 | B2 |
8357144 | Whitman et al. | Jan 2013 | B2 |
8365633 | Simaan et al. | Feb 2013 | B2 |
8365972 | Aranyi et al. | Feb 2013 | B2 |
8371492 | Aranyi et al. | Feb 2013 | B2 |
8372057 | Cude et al. | Feb 2013 | B2 |
8391957 | Carlson et al. | Mar 2013 | B2 |
8403926 | Nobis et al. | Mar 2013 | B2 |
8403949 | Palmer et al. | Mar 2013 | B2 |
8418904 | Wenchell et al. | Apr 2013 | B2 |
8424739 | Racenet et al. | Apr 2013 | B2 |
8454585 | Whitman | Jun 2013 | B2 |
8505802 | Viola et al. | Aug 2013 | B2 |
8517241 | Nicholas et al. | Aug 2013 | B2 |
8523043 | Ullrich et al. | Sep 2013 | B2 |
8551076 | Duval et al. | Oct 2013 | B2 |
8561871 | Rajappa et al. | Oct 2013 | B2 |
8561874 | Scirica | Oct 2013 | B2 |
8602287 | Yates et al. | Dec 2013 | B2 |
8623000 | Humayun et al. | Jan 2014 | B2 |
8627995 | Smith et al. | Jan 2014 | B2 |
8632463 | Drinan et al. | Jan 2014 | B2 |
8636766 | Milliman et al. | Jan 2014 | B2 |
8647258 | Aranyi et al. | Feb 2014 | B2 |
8652121 | Quick et al. | Feb 2014 | B2 |
8657174 | Yates et al. | Feb 2014 | B2 |
8657177 | Scirica et al. | Feb 2014 | B2 |
8672206 | Aranyi et al. | Mar 2014 | B2 |
8696552 | Whitman | Apr 2014 | B2 |
8708213 | Shelton, IV et al. | Apr 2014 | B2 |
8715306 | Faller et al. | May 2014 | B2 |
8752749 | Moore et al. | Jun 2014 | B2 |
8758391 | Swayze et al. | Jun 2014 | B2 |
8806973 | Ross et al. | Aug 2014 | B2 |
8808311 | Heinrich et al. | Aug 2014 | B2 |
8820605 | Shelton, IV | Sep 2014 | B2 |
8851355 | Aranyi et al. | Oct 2014 | B2 |
8858571 | Shelton, IV et al. | Oct 2014 | B2 |
8875972 | Weisenburgh, II et al. | Nov 2014 | B2 |
8888762 | Whitman | Nov 2014 | B2 |
8893946 | Boudreaux et al. | Nov 2014 | B2 |
8899462 | Kostrzewski et al. | Dec 2014 | B2 |
8905289 | Patel et al. | Dec 2014 | B2 |
8919630 | Milliman | Dec 2014 | B2 |
8931680 | Milliman | Jan 2015 | B2 |
8939344 | Olson et al. | Jan 2015 | B2 |
8950646 | Viola | Feb 2015 | B2 |
8960519 | Whitman et al. | Feb 2015 | B2 |
8961396 | Azarbarzin et al. | Feb 2015 | B2 |
8967443 | McCuen | Mar 2015 | B2 |
8968276 | Zemlok et al. | Mar 2015 | B2 |
8968337 | Whitfield et al. | Mar 2015 | B2 |
8992422 | Spivey et al. | Mar 2015 | B2 |
9016545 | Aranyi et al. | Apr 2015 | B2 |
9023014 | Chowaniec et al. | May 2015 | B2 |
9033868 | Whitman et al. | May 2015 | B2 |
9055943 | Zemlok et al. | Jun 2015 | B2 |
9064653 | Prest et al. | Jun 2015 | B2 |
9072515 | Hall et al. | Jul 2015 | B2 |
9113847 | Whitman et al. | Aug 2015 | B2 |
9113875 | Viola et al. | Aug 2015 | B2 |
9113876 | Zemlok et al. | Aug 2015 | B2 |
9113899 | Garrison et al. | Aug 2015 | B2 |
9216013 | Scirica et al. | Dec 2015 | B2 |
9241712 | Zemlok et al. | Jan 2016 | B2 |
9282961 | Whitman et al. | Mar 2016 | B2 |
9282963 | Bryant | Mar 2016 | B2 |
9295522 | Kostrzewski | Mar 2016 | B2 |
9307986 | Hall et al. | Apr 2016 | B2 |
9717498 | Aranyi et al. | Aug 2017 | B2 |
9814463 | Williams | Nov 2017 | B2 |
20010031975 | Whitman et al. | Oct 2001 | A1 |
20020049454 | Whitman et al. | Apr 2002 | A1 |
20020165541 | Whitman | Nov 2002 | A1 |
20030038938 | Jung et al. | Feb 2003 | A1 |
20030165794 | Matoba | Sep 2003 | A1 |
20040034369 | Sauer et al. | Feb 2004 | A1 |
20040111012 | Whitman | Jun 2004 | A1 |
20040133189 | Sakurai | Jul 2004 | A1 |
20040153124 | Whitman | Aug 2004 | A1 |
20040176751 | Weitzner et al. | Sep 2004 | A1 |
20040193146 | Lee et al. | Sep 2004 | A1 |
20050125027 | Knodel et al. | Jun 2005 | A1 |
20050131442 | Yachia et al. | Jun 2005 | A1 |
20060142656 | Malackowski et al. | Jun 2006 | A1 |
20060142740 | Sherman et al. | Jun 2006 | A1 |
20060142744 | Boutoussov | Jun 2006 | A1 |
20060259073 | Miyamoto et al. | Nov 2006 | A1 |
20060278680 | Viola et al. | Dec 2006 | A1 |
20060284730 | Schmid et al. | Dec 2006 | A1 |
20070023476 | Whitman et al. | Feb 2007 | A1 |
20070023477 | Whitman et al. | Feb 2007 | A1 |
20070027469 | Smith et al. | Feb 2007 | A1 |
20070029363 | Popov | Feb 2007 | A1 |
20070084897 | Shelton et al. | Apr 2007 | A1 |
20070102472 | Shelton | May 2007 | A1 |
20070152014 | Gillum et al. | Jul 2007 | A1 |
20070175947 | Ortiz et al. | Aug 2007 | A1 |
20070175949 | Shelton et al. | Aug 2007 | A1 |
20070175950 | Shelton et al. | Aug 2007 | A1 |
20070175951 | Shelton et al. | Aug 2007 | A1 |
20070175955 | Shelton et al. | Aug 2007 | A1 |
20070270784 | Smith et al. | Nov 2007 | A1 |
20080029570 | Shelton et al. | Feb 2008 | A1 |
20080029573 | Shelton et al. | Feb 2008 | A1 |
20080029574 | Shelton et al. | Feb 2008 | A1 |
20080029575 | Shelton et al. | Feb 2008 | A1 |
20080058801 | Taylor et al. | Mar 2008 | A1 |
20080109012 | Falco et al. | May 2008 | A1 |
20080110958 | McKenna et al. | May 2008 | A1 |
20080147089 | Loh et al. | Jun 2008 | A1 |
20080167736 | Swayze et al. | Jul 2008 | A1 |
20080185419 | Smith et al. | Aug 2008 | A1 |
20080188841 | Tomasello et al. | Aug 2008 | A1 |
20080197167 | Viola et al. | Aug 2008 | A1 |
20080208195 | Shores et al. | Aug 2008 | A1 |
20080237296 | Boudreaux et al. | Oct 2008 | A1 |
20080251561 | Eades et al. | Oct 2008 | A1 |
20080255413 | Zemlok et al. | Oct 2008 | A1 |
20080255607 | Zemlok | Oct 2008 | A1 |
20080262654 | Omori et al. | Oct 2008 | A1 |
20080308603 | Shelton et al. | Dec 2008 | A1 |
20090012533 | Barbagli et al. | Jan 2009 | A1 |
20090090763 | Zemlok et al. | Apr 2009 | A1 |
20090099876 | Whitman | Apr 2009 | A1 |
20090138006 | Bales et al. | May 2009 | A1 |
20090171147 | Lee et al. | Jul 2009 | A1 |
20090182193 | Whitman et al. | Jul 2009 | A1 |
20090209946 | Swayze et al. | Aug 2009 | A1 |
20090209990 | Yates et al. | Aug 2009 | A1 |
20090254094 | Knapp et al. | Oct 2009 | A1 |
20090299141 | Downey et al. | Dec 2009 | A1 |
20100023022 | Zeiner et al. | Jan 2010 | A1 |
20100069942 | Shelton, IV | Mar 2010 | A1 |
20100147922 | Olson | Jun 2010 | A1 |
20100193568 | Scheib et al. | Aug 2010 | A1 |
20100211053 | Ross et al. | Aug 2010 | A1 |
20100225073 | Porter et al. | Sep 2010 | A1 |
20110006101 | Hall et al. | Jan 2011 | A1 |
20110017801 | Zemlok et al. | Jan 2011 | A1 |
20110071508 | Duval et al. | Mar 2011 | A1 |
20110077673 | Grubac et al. | Mar 2011 | A1 |
20110121049 | Malinouskas et al. | May 2011 | A1 |
20110125138 | Malinouskas et al. | May 2011 | A1 |
20110139851 | McCuen | Jun 2011 | A1 |
20110155783 | Rajappa et al. | Jun 2011 | A1 |
20110155786 | Shelton, IV | Jun 2011 | A1 |
20110172648 | Jeong | Jul 2011 | A1 |
20110174009 | Iizuka et al. | Jul 2011 | A1 |
20110174099 | Ross et al. | Jul 2011 | A1 |
20110184245 | Xia et al. | Jul 2011 | A1 |
20110204119 | McCuen | Aug 2011 | A1 |
20110218522 | Whitman | Sep 2011 | A1 |
20110276057 | Conlon et al. | Nov 2011 | A1 |
20110290854 | Timm et al. | Dec 2011 | A1 |
20110295242 | Spivey et al. | Dec 2011 | A1 |
20110295269 | Swensgard et al. | Dec 2011 | A1 |
20120000962 | Racenet et al. | Jan 2012 | A1 |
20120074199 | Olson et al. | Mar 2012 | A1 |
20120089131 | Zemlok et al. | Apr 2012 | A1 |
20120104071 | Bryant | May 2012 | A1 |
20120116368 | Viola | May 2012 | A1 |
20120143002 | Aranyi et al. | Jun 2012 | A1 |
20120172924 | Allen, IV | Jul 2012 | A1 |
20120211542 | Racenet | Aug 2012 | A1 |
20120223121 | Viola et al. | Sep 2012 | A1 |
20120245428 | Smith et al. | Sep 2012 | A1 |
20120253329 | Zemlok et al. | Oct 2012 | A1 |
20120310220 | Malkowski et al. | Dec 2012 | A1 |
20120323226 | Chowaniec et al. | Dec 2012 | A1 |
20120330285 | Hartoumbekis et al. | Dec 2012 | A1 |
20130093149 | Saur et al. | Apr 2013 | A1 |
20130181035 | Milliman | Jul 2013 | A1 |
20130184704 | Beardsley et al. | Jul 2013 | A1 |
20130214025 | Zemlok et al. | Aug 2013 | A1 |
20130274722 | Kostrzewski et al. | Oct 2013 | A1 |
20130282052 | Aranyi et al. | Oct 2013 | A1 |
20130292451 | Viola et al. | Nov 2013 | A1 |
20130313304 | Shelton, IV et al. | Nov 2013 | A1 |
20130317486 | Nicholas et al. | Nov 2013 | A1 |
20130319706 | Nicholas et al. | Dec 2013 | A1 |
20130324978 | Nicholas et al. | Dec 2013 | A1 |
20130324979 | Nicholas et al. | Dec 2013 | A1 |
20130334281 | Williams | Dec 2013 | A1 |
20140012236 | Williams et al. | Jan 2014 | A1 |
20140012237 | Pribanic et al. | Jan 2014 | A1 |
20140012289 | Snow et al. | Jan 2014 | A1 |
20140025046 | Williams et al. | Jan 2014 | A1 |
20140110455 | Ingmanson et al. | Apr 2014 | A1 |
20140207125 | Applegate et al. | Jul 2014 | A1 |
20140207182 | Zergiebel et al. | Jul 2014 | A1 |
20140207185 | Goble et al. | Jul 2014 | A1 |
20140236174 | Williams et al. | Aug 2014 | A1 |
20140276932 | Williams et al. | Sep 2014 | A1 |
20140299647 | Scirica et al. | Oct 2014 | A1 |
20140303668 | Nicholas et al. | Oct 2014 | A1 |
20140358129 | Zergiebel et al. | Dec 2014 | A1 |
20140361068 | Aranyi et al. | Dec 2014 | A1 |
20140365235 | DeBoer et al. | Dec 2014 | A1 |
20140373652 | Zergiebel et al. | Dec 2014 | A1 |
20150014392 | Williams et al. | Jan 2015 | A1 |
20150048144 | Whitman | Feb 2015 | A1 |
20150076205 | Zergiebel | Mar 2015 | A1 |
20150080912 | Sapre | Mar 2015 | A1 |
20150112381 | Richard | Apr 2015 | A1 |
20150122870 | Zemlok et al. | May 2015 | A1 |
20150133224 | Whitman et al. | May 2015 | A1 |
20150150547 | Ingmanson et al. | Jun 2015 | A1 |
20150150574 | Richard et al. | Jun 2015 | A1 |
20150157320 | Zergiebel et al. | Jun 2015 | A1 |
20150157321 | Zergiebel et al. | Jun 2015 | A1 |
20150164502 | Richard et al. | Jun 2015 | A1 |
20150201931 | Zergiebel et al. | Jul 2015 | A1 |
20150272577 | Zemlok et al. | Oct 2015 | A1 |
20150297199 | Nicholas et al. | Oct 2015 | A1 |
20150303996 | Calderoni | Oct 2015 | A1 |
20150320420 | Penna et al. | Nov 2015 | A1 |
20150327850 | Kostrzewski | Nov 2015 | A1 |
20150342601 | Williams et al. | Dec 2015 | A1 |
20150342603 | Zergiebel et al. | Dec 2015 | A1 |
20150374366 | Zergiebel et al. | Dec 2015 | A1 |
20150374370 | Zergiebel et al. | Dec 2015 | A1 |
20150374371 | Richard et al. | Dec 2015 | A1 |
20150374372 | Zergiebel et al. | Dec 2015 | A1 |
20150374449 | Chowaniec et al. | Dec 2015 | A1 |
20150380187 | Zergiebel et al. | Dec 2015 | A1 |
20160095585 | Zergiebel et al. | Apr 2016 | A1 |
20160095596 | Scirica et al. | Apr 2016 | A1 |
20160106406 | Cabrera et al. | Apr 2016 | A1 |
20160113648 | Zergiebel et al. | Apr 2016 | A1 |
20160113649 | Zergiebel et al. | Apr 2016 | A1 |
20160206315 | Olson | Jul 2016 | A1 |
20180125491 | Aranyi | May 2018 | A1 |
20210177411 | Williams | Jun 2021 | A1 |
Number | Date | Country |
---|---|---|
2451558 | Jan 2003 | CA |
1547454 | Nov 2004 | CN |
1957854 | May 2007 | CN |
101495046 | Jul 2009 | CN |
101856251 | Oct 2010 | CN |
102247182 | Nov 2011 | CN |
102008053842 | May 2010 | DE |
0705571 | Apr 1996 | EP |
1563793 | Aug 2005 | EP |
1759652 | Mar 2007 | EP |
1769754 | Apr 2007 | EP |
1908412 | Apr 2008 | EP |
1917929 | May 2008 | EP |
1952769 | Aug 2008 | EP |
2090247 | Aug 2009 | EP |
2245994 | Nov 2010 | EP |
2316345 | May 2011 | EP |
2377472 | Oct 2011 | EP |
2668910 | Dec 2013 | EP |
2815705 | Dec 2014 | EP |
2333509 | Feb 2010 | ES |
2861574 | May 2005 | FR |
2005125075 | May 2005 | JP |
20120022521 | Mar 2012 | KR |
2011108840 | Sep 2011 | WO |
2012040984 | Apr 2012 | WO |
Entry |
---|
Extended European Search Report corresponding to International Application No. EP 14 18 4882.0 dated May 12, 2015. |
Canadian Office Action corresponding to International Application No. CA 2640399 dated May 7, 2015. |
Japanese Office Action corresponding to International Application No. JP 2011-197365 dated Mar. 23, 2015. |
Japanese Office Action corresponding to International Application No. JP 2011-084092 dated May 20, 2015. |
Japanese Office Action corresponding to International Application No. JP 2014-148482 dated Jun. 2, 2015. |
Extended European Search Report corresponding to International Application No. EP 14 18 9358.6 dated Jul. 8, 2015. |
Extended European Search Report corresponding to International Application No. EP 14 19 6148.2 dated Apr. 23, 2015. |
Partial European Search Report corresponding to International Application No. EP 14 19 6704.2 dated May 11, 2015. |
Australian Office Action corresponding to International Application No. AU 2010241367 dated Aug. 20, 2015. |
Partial European Search Report corresponding to International Application No. EP 14 19 9783.3 dated Sep. 3, 2015. |
Extended European Search Report corresponding to International Application No. EP 15 16 9962.6 dated Sep. 14, 2015. |
Extended European Search Report corresponding to International Application No. EP 15 15 1076.5 dated Apr. 22, 2015. |
Japanese Office Action corresponding to International Application No. JP 2011-084092 dated Jan. 14, 2016. |
Extended European Search Report corresponding to International Application No. EP 12 19 7970.2 dated Jan. 28, 2016. |
Chinese Office Action corresponding to International Application No. CN 201210560638.1 dated Oct. 21, 2015. |
European Office Action corresponding to International Application No. EP 14 15 9056.2 dated Oct. 26, 2015. |
Australian Examination Report No. 1 corresponding to International Application No. AU 2015200153 dated Dec. 11, 2015. |
Australian Examination Report No. 1 corresponding to International Application No. AU 2014204542 dated Jan. 7, 2016. |
Chinese Office Action corresponding to International Application No. CN 201310125449.6 dated Feb. 3, 2016. |
Extended European Search Report corresponding to International Application No. EP 15 19 0245.9 dated Jan. 28, 2016. |
Extended European Search Report corresponding to International Application No. EP 15 16 7793.7 dated Apr. 5, 2016. |
European Office Action corresponding to International Application No. EP 14 18 4882.0 dated Apr. 25, 2016. |
Extended European Search Report corresponding to International Application No. EP 14 19 6704.2 dated Sep. 24, 2015. |
International Search Report and Written Opinion corresponding to Int'l Appln. No. PCT/US2015/051837, dated Dec. 21, 2015. |
Extended European Search Report corresponding to International Application No. EP 14 19 7563.1 dated Aug. 5, 2015. |
Partial European Search Report corresponding to International Application No. EP 15 19 0643.5 dated Feb. 26, 2016. |
Extended European Search Report corresponding to International Application No. EP 15 16 6899.3 dated Feb. 3, 2016. |
Extended European Search Report corresponding to International Application No. EP 14 19 9783.3 dated Dec. 22, 2015. |
Extended European Search Report corresponding to International Application No. EP 15 17 3807.7 dated Nov. 24, 2015. |
Extended European Search Report corresponding to International Application No. EP 15 19 0760.7 dated Apr. 1, 2016. |
Extended European Search Report corresponding to International Application No. EP 15 17 3803.6 dated Nov. 24, 2015. |
Extended European Search Report corresponding to International Application No. EP 15 17 3804.4 dated Nov. 24, 2015. |
Extended European Search Report corresponding to International Application No. EP 15 18 8539.9 dated Feb. 17, 2016. |
Extended European Search Report corresponding to International Application No. EP 15 17 3910.9 dated Nov. 13, 2015. |
European Office Action corresponding to International Application No. EP 14 15 2236.7 dated Aug. 11, 2015. |
Extended European Search Report corresponding to International Application No. EP 15 18 4915.5 dated Jan. 5, 2016. |
Chinese Office Action corresponding to counterpart Int'l Appln. No. CN 201310369318.2 dated Jun. 28, 2016. |
Chinese Office Action (with English translation), dated Jul. 4, 2016, corresponding to Chinese Patent Application No. 2015101559718; 23 total pages. |
European Search Report EP 15 156 035.6 dated Aug. 10, 2016. |
European Search Report corresponding to EP 15 184 915.5-1654 dated Sep. 16, 2016. |
Australian Examination Report No. 1 corresponding to International Application No. AU 2013205872 dated Oct. 19, 2016. |
Australian Examination Report from Appl. No. AU 2013205840 dated Nov. 3, 2016. |
Notification of Transmittal of the International Search Report and The Written Opinion of the International Searching Authority issued in corresponding application No. PCT/US2016/027042 dated Jul. 12, 2016. |
International Search Report and Written Opinion dated Nov. 28, 2022, issued in corresponding international application No. PCT/IB2022/056050, 16 pages. |
Number | Date | Country | |
---|---|---|---|
20230011980 A1 | Jan 2023 | US |